If you’re on the hunt for stocks to watch today, Menlo Therapeutics Inc. (NASDAQ:MNLO) is a stock to give close attention to. The company shares are trading 10.75% or 0.5 points up from last closing price of $4.65, reaching $5.15 at last check. The MNLO share price has risen in 3 of the last 5 days and is down -11.43% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -39,944 shares, and in total 146956 shares valued at $756823 were seen changing hands compared with 186900 shares valued at $869085 recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in MNLO stock for the next couple of days.
Menlo Therapeutics Inc. (MNLO) shares have notched a 3-month decline of about -11.43%, but has still advanced 0.22% year to date. By comparison, the stock sank -16.52% over the past 12 months, while it jumped 14.25% over the 1 month. The company’s market cap is around $115.92M, with its short interest ratio standing at 3.71%.
In the current trading session for MNLO, the stock witnessed two major price actions, it rose to a high of $5.45 and was down as much as $4.88 at one point. The high recorded is very low when compared to their 52-week high which is $2.69. The 52-week high is now at -41.7 distance from current price. Their recent low of $9.03 represents a 95.72% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for MNLO is $17.83, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
MNLO‘s last price was up 1.95% as compared to the average trading price of 50 days recorded at $5.05 while enlarging the period to 200 trading days, the average closing price was $4.8. At present, there are 24.93 million in the total number of common shares owned by the public and among those 19.73 million shares have been available to trade. The percentage of shares being held by the company management was 2.6% while institutions stake was 79.5%. The company has generated negative returns on equity over the last 12 months (-64.2%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the MNLO stock, there is another set of technicals that should be looked into and considered. Its -5.07% decline from moving average of $5.43 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Menlo Therapeutics Inc. — 2 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $18 on shares of Menlo Therapeutics Inc. (NASDAQ:MNLO), which corresponds to 241.56% upside potential than its current market price of $5.15 and implies potential despite the recent advance in the price. However, their current target price has fallen from $18 a month ago and is down handily from the consensus target of $18 a quarter ago.
Let’s briefly check the hedge fund interest towards MNLO stock. Virtu Financial LLC changed position in the company and now owns 12,636 shares worth $65,075, SEC documents show. Russell Investments Group Ltd. cut assets in the stock as 34107.31 shares have been sold, reducing its stake by -15.2% to 28,923 shares which are currently valued at $148,954. In addition, Orbimed Advisors LLC recently reported that it now owns 662,600 shares making a total of $3,412,390 based on the recent price. This refelects a change of -1.6% in their ownership.